WHO warns Asia-Pacific AMR plans lack financing
The WHO Western Pacific Regional Office says countries in Asia and the Pacific are strengthening antimicrobial resistance plans, but most remain unfunded. The financing gap threatens efforts to curb drug-resistant infections and could slow work on laboratories, infection prevention, antibiotic stewardship, and surveillance. WHO’s update points to a need for sustained investment in health security and AMR implementation.
The WHO Western Pacific Regional Office says countries and territories across Asia and the Pacific are refining antimicrobial resistance plans. Even so, most of those plans lack financing, according to the update. The region's AMR work spans laboratory capacity, infection prevention and control, antibiotic stewardship, and surveillance.
Because funding is not secured, those implementation areas may fall behind stated policy goals. WHO frames the issue within health security and calls for sustained investment in AMR implementation. The supplied material does not identify partners, funding amounts, target groups, or timelines.
If AMR plans remain unfunded, patients in Asia and the Pacific could face greater risks from infections that are harder to treat. Health workers and public health systems may struggle to maintain laboratory capacity, infection prevention, antibiotic stewardship, and surveillance. NGOs, grantmakers, and civil society groups focused on health security could see implementation gaps persist, making coordinated investment and systems strengthening more important. The impact may be gradual, but it could affect the region's ability to respond to drug-resistant threats.